NSABP FC-11

NSABP FC-11

A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated

Protocol Chair: Shannon Puhalla, MD

Protocol Officer: Carmen Allegra, MD

Patient Population:
Patients with KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer

Target Accrual: 35 patients

Status: Active, Not Recruiting

ClinicialTrials.gov Identifier: NCT03457896